Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

D E Furst; F C Breedveld; J R  Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease

doi:10.1136/ard.2005.044941

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

D E Furst^*
, F C Breedveld
, J R Kalden
, J S Smolen
, G R Burmester
, J W J Bijlsma
, M Dougados
, P Emery
, E C Keystone
, L Klareskog
, P J Mease

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

155 Citations (Scopus)

Original language	English
Pages (from-to)	2-14
Number of pages	13
Journal	Annals of the Rheumatic Diseases
Volume	64
DOIs	https://doi.org/10.1136/ard.2005.044941
Publication status	Published - Nov-2005
Externally published	Yes
Event	7th International Symposium on Advances in Targeted Therapies - , Italy Duration: 6-Apr-2005 → 10-Apr-2005

Keywords

PLACEBO-CONTROLLED TRIAL
ACTIVE ANKYLOSING-SPONDYLITIS
MONOCLONAL-ANTIBODY THERAPY
GIANT-CELL ARTERITIS
RANDOMIZED CONTROLLED-TRIAL
PRIMARY SJOGRENS-SYNDROME
HEPATITIS-C INFECTION
PLAQUE-TYPE PSORIASIS
LONG-TERM EFFICACY
OPEN-LABEL TRIAL

Access to Document

10.1136/ard.2005.044941

Handle.net

Persistent link

Embargoed Document

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
Final publisher's version, 188 KB
Request copy

Cite this

Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., & Mease, P. J. (2005). Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Annals of the Rheumatic Diseases, 64, 2-14. https://doi.org/10.1136/ard.2005.044941

@article{503d68616cfb4853836ab65627e2fb4a,

title = "Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005",

keywords = "PLACEBO-CONTROLLED TRIAL, ACTIVE ANKYLOSING-SPONDYLITIS, MONOCLONAL-ANTIBODY THERAPY, GIANT-CELL ARTERITIS, RANDOMIZED CONTROLLED-TRIAL, PRIMARY SJOGRENS-SYNDROME, HEPATITIS-C INFECTION, PLAQUE-TYPE PSORIASIS, LONG-TERM EFFICACY, OPEN-LABEL TRIAL",

author = "Furst, \{D E\} and Breedveld, \{F C\} and Kalden, \{J R\} and Smolen, \{J S\} and Burmester, \{G R\} and Bijlsma, \{J W J\} and M Dougados and P Emery and Keystone, \{E C\} and L Klareskog and Mease, \{P J\}",

year = "2005",

month = nov,

doi = "10.1136/ard.2005.044941",

language = "English",

volume = "64",

pages = "2--14",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

note = "7th International Symposium on Advances in Targeted Therapies ; Conference date: 06-04-2005 Through 10-04-2005",

}

Furst, DE, Breedveld, FC, Kalden, JR, Smolen, JS, Burmester, GR, Bijlsma, JWJ, Dougados, M, Emery, P, Keystone, EC, Klareskog, L & Mease, PJ 2005, 'Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005', Annals of the Rheumatic Diseases, vol. 64, pp. 2-14. https://doi.org/10.1136/ard.2005.044941

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. / Furst, D E; Breedveld, F C; Kalden, J R et al.
In: Annals of the Rheumatic Diseases, Vol. 64, 11.2005, p. 2-14.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

AU - Furst, D E

AU - Breedveld, F C

AU - Kalden, J R

AU - Smolen, J S

AU - Burmester, G R

AU - Bijlsma, J W J

AU - Dougados, M

AU - Emery, P

AU - Keystone, E C

AU - Klareskog, L

AU - Mease, P J

PY - 2005/11

Y1 - 2005/11

KW - PLACEBO-CONTROLLED TRIAL

KW - ACTIVE ANKYLOSING-SPONDYLITIS

KW - MONOCLONAL-ANTIBODY THERAPY

KW - GIANT-CELL ARTERITIS

KW - RANDOMIZED CONTROLLED-TRIAL

KW - PRIMARY SJOGRENS-SYNDROME

KW - HEPATITIS-C INFECTION

KW - PLAQUE-TYPE PSORIASIS

KW - LONG-TERM EFFICACY

KW - OPEN-LABEL TRIAL

U2 - 10.1136/ard.2005.044941

DO - 10.1136/ard.2005.044941

M3 - Article

SN - 0003-4967

VL - 64

SP - 2

EP - 14

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

T2 - 7th International Symposium on Advances in Targeted Therapies

Y2 - 6 April 2005 through 10 April 2005

ER -

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JWJ et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Annals of the Rheumatic Diseases. 2005 Nov;64:2-14. doi: 10.1136/ard.2005.044941